Synaptogenix, Inc. SNPX
We take great care to ensure that the data presented and summarized in this overview for Synaptogenix, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding SNPX
View allLatest Institutional Activity in SNPX
Top Purchases
Top Sells
About SNPX
Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc. has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University. The company was incorporated in 2012 and is headquartered in New York, New York.
Insider Transactions at SNPX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 16
2022
|
Alan J Tuchman Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
27,000
-45.0%
|
$27,000
$1.17 P/Share
|
|
Dec 16
2022
|
Bruce Bernstein Director |
SELL
Open market or private sale
|
Direct |
22,500
-44.93%
|
$22,500
$1.17 P/Share
|
|
Dec 16
2022
|
Daniel L. Alkon President and CSO |
SELL
Open market or private sale
|
Direct |
19,688
-35.64%
|
$19,688
$1.17 P/Share
|
|
Dec 16
2022
|
Jonathan Schechter Director |
SELL
Open market or private sale
|
Direct |
20,250
-41.54%
|
$20,250
$1.17 P/Share
|
|
Dec 16
2022
|
Joshua Silverman Director |
SELL
Open market or private sale
|
Direct |
19,012
-33.21%
|
$19,012
$1.17 P/Share
|
|
Dec 16
2022
|
Robert Weinstein Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
27,000
-44.85%
|
$27,000
$1.17 P/Share
|
|
Dec 16
2022
|
William S. Singer Director |
SELL
Open market or private sale
|
Direct |
27,000
-45.0%
|
$27,000
$1.17 P/Share
|
|
Jul 13
2021
|
Joshua Silverman Director |
BUY
Grant, award, or other acquisition
|
Direct |
90,000
+46.15%
|
-
|
|
Jul 13
2021
|
Daniel L. Alkon President and CSO |
BUY
Grant, award, or other acquisition
|
Direct |
80,000
+46.65%
|
-
|
|
Jul 13
2021
|
Bruce Bernstein Director |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+49.96%
|
-
|
|
Jul 13
2021
|
Robert Weinstein Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
60,000
+49.92%
|
-
|
|
Jul 13
2021
|
Jonathan Schechter Director |
BUY
Grant, award, or other acquisition
|
Direct |
45,000
+48.0%
|
-
|
|
Jul 13
2021
|
George Perry Director |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+50.0%
|
-
|
|
Jul 13
2021
|
William S. Singer Director |
BUY
Grant, award, or other acquisition
|
Direct |
60,000
+50.0%
|
-
|
|
Jul 13
2021
|
Alan J Tuchman Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
60,000
+50.0%
|
-
|
|
Jun 14
2021
|
Joshua Silverman Director |
BUY
Open market or private purchase
|
Direct |
10,000
+40.0%
|
$80,000
$8.3 P/Share
|
|
Jun 14
2021
|
Daniel L. Alkon President and CSO |
BUY
Open market or private purchase
|
Direct |
10,000
+46.55%
|
$80,000
$8.26 P/Share
|